Clinical utility of serum HER-2/neu testing on the bayer immuno 1® automated system in breast cancer

Anticancer Research

Volumn 21, Issue 2 B, 2001, Pages 1465-1470

  Cook, G B ^a   Neaman, I E ^a   Goldblatt, J L ^a   Cambetas, D R ^a   Hussain, M ^a   Luftner D ^a   Yeung, K K ^a   Chan, D W ^a   Schwartz, M K ^a   Allard, W J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Breast cancer; Immuno 1 automated system; Serum HER 2 neu

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY AUTOMATION; ONCOGENE NEU; PRIORITY JOURNAL; REPRODUCIBILITY;

AUTOMATION; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; REAGENT KITS, DIAGNOSTIC; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY;

EID: 0035000489     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. The neu oncogene encodes an epidermal growth factor receptor-related protein
2. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas
3. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
4. The c-erbB-2 protein in oncogenesis: Molecular structure to molecular epidemiology
5. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells SK-BR-3
6. Automated assay for HER-2/neu in serum
7. Clinical utility of an automated serum HER-2/neu assay in monitoring patients with metastatic breast cancer
8. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185
9. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
10. The HER-2/neu oncogene in breast cancer. Prognostic factor, predictive factor, and target for therapy
11. Detection of c-erbB-2 related protein in sera from breast cancer patients
12. Tissue expression and serum levels of HER-2/neu in patients with breast cancer
13. Consequences of discordances between different methods of HER2/neu measurement in breast cancer
14. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
15. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
16. Prognostic importance of c-erbB-2 expression in breast cancer
17. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
18. Expression of the c-erbB-2 protein in normal and transformed cells
19. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: Immunohistological assessment correlates with gene amplification
20. C-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
21. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer
22. Comparison between western blotting, immunohistochemistry and ELISA assay for p185 neu quantitation in breast cancer specimens
23. Elevated circulating c-neu oncogene product in patients with breast cancer
24. The neu-oncogene product in serum and tissue of patients with breast carcinoma
25. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer
26. Utility of c-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: Comparison with carcinoembryonic antigen and CA 15.3
27. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
28. Baseline serum HER2 (sHER2) levels in the pivotal herceptin breast cancer trials: A comparison of 2 ELISA methods